UBE3A Dosage Imbalance as a Molecular Framework Linking Angelman Syndrome and Dup15q-Associated Autism Phenotypes.

Intrafamilial Variability in NRXN1-Associated Neurodevelopmental Disorders: Clinical and Genetic Insights from a Family Case Study with Literature Review

The concept that NRXN1 deletions alone do not determine clinical outcome but rather act within a broader genetic and biological context is supported, whereby NRXN1 deletions act as susceptibility factors whose phenotypic consequences are shaped by additional genetic and modifying influences.

The SNRPN Bipartite Imprinting Centre in Region 15q11–q13 and Its Epigenetic Role in the Pursuit of a Cure for Angelman Syndrome

Angelman syndrome is a severe neurodevelopmental disorder arising from functional loss of the maternal allele of UBE3A, a gene that sits within a cluster of imprinted loci on the long arm of chromosome 15. Expression across this region is governed by a bipartite imprinting centre associated with the SNRPN gene, made up of two physically separated but functionally interdependent elements: the Prader–Willi syndrome smallest region of deletion overlap and the Angelman syndrome smallest region of deletion overlap. Together these elements establish, in the germline, and maintain, throughout somatic life, the parent-of-origin-specific expression pattern that distinguishes Angelman syndrome from its reciprocal disorder, Prader–Willi syndrome. Because the paternal copy of UBE3A remains structurally intact in most patients with Angelman syndrome, merely silenced by a long non-coding antisense transcript whose own expression is dictated by the imprinting centre, this locus has become the focal point of an unusually concentrated translational effort: rather than replacing a missing gene, contemporary therapeutic strategies aim to reverse an epigenetic mark and thereby unmask a dormant but functional allele. This review draws together the structural biology of the bipartite imprinting centre, the molecular events that establish and maintain its parent-specific epigenotype, the diagnostic and clinical consequences of its disruption, and the rapidly maturing pipeline of antisense oligonucleotides, small molecules, and genome- or epigenome-editing tools designed to exploit this biology therapeutically. Recent clinical trial data, including electroencephalographic and behavioural endpoints from antisense oligonucleotide programmes, are critically appraised alongside preclinical work on CRISPR-based epigenetic editing of the imprinting centre itself, an approach with the conceptual elegance of intervening at the very switch that imprinting biology depends upon. The review concludes that while no disease-modifying therapy is yet approved, the convergence of detailed mechanistic understanding of the SNRPN bipartite imprinting centre with scalable epigenetic editing technologies represents the most plausible route towards a transformative, rather than purely symptomatic, treatment for Angelman syndrome, while candidly addressing the developmental, safety and translational obstacles that remain.

Emerging Therapies for Angelman Syndrome.

X-linked SYTL4 missense variant disrupts RAB27A-dependent vesicle trafficking and synaptic transmission in autism.

The findings implicate disrupted SYTL4-RAB27A-dependent vesicle trafficking in ASD pathogenesis and identify SYTL4 and RAB27A as previously unrecognized contributors to autism-associated synaptic deficits and behavior.

Delineation of a Novel Mirror Syndrome: NFIC Variants Cause Syndromic Intellectual Disability With Macrocephaly.

Nuclear factor I (NFI) transcription factors regulate neural stem and progenitor differentiation during brain development. While NFIA, NFIB, and NFIX are linked to neurodevelopmental disorders, the role of NFIC (MIM: 600729) in human disease remains unclear. This study aimed to determine whether NFIC contributes to a neurodevelopmental syndrome, define its phenotype, and assess dosage-dependent effects. We established the first cohort of 11 individuals, including NFIC deletions and single nucleotide variants. Genotype-phenotype correlations, including critical region mapping, were performed. Murine data and bioinformatics were integrated to explore underlying pathomechanisms. We report 11 individuals with NFIC variants, including four with de novo SNVs and seven with deletions encompassing the gene, of whom nine have not been previously reported. A core phenotype of syndromic intellectual disability and macrocephaly was delineated. Opposing cranial phenotypes relative to proximal 19p13.3 duplication cases support a dosage-sensitive effect and a mirror-syndrome model. NFIC-related disorder represents a novel neurodevelopmental syndrome characterized by intellectual disability and macrocephaly, highlighting the importance of NFIC dosage supporting a mirror-syndrome model.

Unraveling the impact of trip12 on neurodevelopment: insights from a zebrafish model

This study provides substantial evidence for the vital role of trip12 in the early stages of development, as homozygous individuals exhibited early mortality by Day 23 post-fertilization, while a substantial mortality rate was observed by Day 35 in ‘heterozygous’ mutants.